Cancer Biomarkers Market Size Anticipated to Reach USD 42.13 billion by 2035

According to a recently published report by Roots Analysis, rising adoption of cancer biomarker tests among patients and healthcare providers, coupled with growing interest of drug developers in personalized medicine is driving the market growth

Cancer Biomarkers Market Overview

The global cancer biomarkers market is expected to reach USD 42.13 billion by 2035, growing at a CAGR of 4.3% during the forecast period till 2035.  

In recent years, the healthcare sector has made significant advancements in cancer treatment options, including targeted therapies, immunotherapies and anti-cancer vaccines. However, clinical cancer research continues to face challenges, marked by high therapy failure rates, limitations, and side effects. Additionally, variability in patient responses to treatments owing to diverse molecular profiles has underscored the need for personalized approaches, like oncology precision medicine. While single-analyte biomarkers like PD-L1, BRAF, and EGFR have proven crucial, they are often insufficient due to individual genomic variations. As a result, biotechnological progress has facilitated the identification of more robust biomarkers, such as TMB, MSI, TILs, SNV, CNV and Indels which assist physicians in the development of personalized treatment and therapies based on patients’ genotypes.

Browse 140+ figures and 135+ market data tables and detailed Table of Content on “Cancer Biomarkers Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK and Other Biomarkers), Type of Cancer (Breast Cancer, Colorectum Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkin Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia), and  Geographical Regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa) here:
https://www.rootsanalysis.com/reports/cancer-biomarkers-market/253.html

Market Drivers

Several factors are propelling the cancer biomarkers market, including the global rise in cancer cases and the growing number of patients requiring diagnostic tests which are driving the demand for these biomarkers. Furthermore, significant advancements in next-generation sequencing (NGS) and polymerase chain reaction (PCR) have enhanced the sensitivity and accuracy of these solutions, allowing the precise identification of biomarkers. This technological evolution, coupled with an increasing shift toward precision medicine and personalized therapeutic strategies, has bolstered the clinical adoption of these solutions. Consequently, big pharmaceutical companies, like Roche and Novartis, are readily investing in cancer biomarker-driven clinical trials, accelerating market growth.

Market Restraints

While the cancer biomarkers market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. The high cost of advanced sequencing technologies and specialized equipment remains a barrier for many diagnostic laboratories and smaller healthcare facilities. Further, technical issues related to sample collection and storage, high capital investments, and extensive timelines for biomarker development are the key challenges that can hinder market expansion. Additionally, unfavorable regulatory and reimbursement scenarios pose significant barriers to the adoption of new biomarkers, making it difficult for the market to continue growing.

Growth Factors

Despite the aforementioned challenges, various growth continues to drive the cancer biomarkers market. One notable factor includes the rising integration of artificial intelligence and machine learning in genomic data analysis, which has significantly improved the ability to distinguish subtle cancer signals from any kind of biological noise. Furthermore, the increasing investment in biomarker research and development is creating substantial growth opportunities in the market. Moreover, the growing elderly population and a surge in cancer cases are further propelling the demand for cancer biomarker solutions.

Cancer Biomarkers Market Segments

Based on the type of biomarkers, the market is segmented into HER2, MET, EGFR, PD-L1, NTRK, ALK and other biomarkers

• The HER2 sub-segment captures the largest revenue share of more than 20% in the cancer biomarkers market, in 2026.
• The EGFR segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 4.8% during the forecast period.

Based on the type of cancer, the market is segmented into Breast Cancer, Colorectum Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkin Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia

• In 2026, breast cancer sub-segment captures the largest revenue share of 25% in the cancer biomarkers market and this trend is unlikely to change during the forecast period.
• The melanoma segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 4.5% during the forecast period.

Based on geographical regions, the market is segmented North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa

• North America dominated the cancer biomarkers market and is likely to account for the largest revenue share of over 50% in 2026.
• Moreover, the cancer biomarkers market in North America is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The cancer biomarkers market report also includes detailed profiles of key players (listed below) that offer these products:

• ARUP Laboratories
• Asper Biogene
• BioReference
• Caris Life Sciences
• CeGaT
• Foundation Medicine
• Genekor Medical
• Guardant Health
• IQVIA Laborateries
• Labcorp
• MedGenome
• NeoGenomics Laboratories
• Nonacus
• OncoDNA
• Quest Diagnostics
• Oxford Gene Technology
• Personal Genome Diagnostics
• PhenoPath
• Positive Biosciences
• Tempus
• Thermo Fisher Scientific
• YuceBio

You Can Download Free Sample PDF Copy Of This Report At:
https://www.rootsanalysis.com/reports/cancer-biomarkers-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com